Conditions: Exudative Age-Related Macular Degeneration Focal Vitreomacular Adhesion
Keywords: AMD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 100
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic vitreolysis and nonsurgical resolution of focal vitreomacular adhesion in AMD subjects where this adhesion may be causally associated with worse prognosis).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Ocriplasmin intervention 2: Sham injection
Intervention descriptions: intervention 1: ocriplasmin intravitreal injection (125 µg) intervention 2: Sham injection

Protocol document: